NCT05169957
Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) treatment 1 active_not_recruiting NCT04904120
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy No drug interventions diagnostic 1 completed NCT03986515
Apatinib Plus SHR1210 in Advanced Mucosal Melanoma treatment 2 unknown_status NCT01961115
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma treatment 2 completed NCT03698019
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma treatment 2 active_not_recruiting NCT06319196
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma treatment 2 recruiting NCT05384496
Axitinib and Nivolumab for the Treatment of Mucosal Melanoma treatment 2 recruiting NCT04622566
Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma treatment 2 unknown_status NCT04462965
Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study treatment 2 recruiting NCT05111574
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery treatment 2 recruiting NCT05086692
A Beta-only IL-2 ImmunoTherapY Study treatment 1 / 2 recruiting NCT01989572
Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery prevention 3 completed NCT03611868
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors treatment 1 / 2 recruiting NCT05655312
MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma No drug interventions treatment 1 / 2 recruiting NCT03602547
Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma. treatment 2 unknown_status NCT05628883
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma treatment 1 recruiting NCT03319693
Molecular Characterization of Primary Mucosal Melanoma No drug interventions Not Available Not Available completed NCT03220009
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma treatment 2 withdrawn NCT00424515
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma treatment 2 completed NCT00937937
Dinaciclib in Treating Patients With Stage IV Melanoma treatment 2 active_not_recruiting NCT04551352
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas treatment 1 completed NCT02129075
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma treatment 2 completed NCT03138642
Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era No drug interventions treatment 2 unknown_status NCT04472806
Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma treatment 2 unknown_status NCT00110019
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery treatment 3 completed NCT05420324
A Study to Assess YH003 in Combination With Pebolizumab and Albumin Paclitaxel Injection in Subjects With Unresectable/Metastatic Mucosal Melanoma treatment 2 recruiting NCT04830124
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6 treatment 2 recruiting NCT03241186
Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma treatment 2 active_not_recruiting NCT02519322
Neoadjuvant and Adjuvant Checkpoint Blockade treatment 2 completed NCT06424626
A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma treatment 1 not_yet_recruiting NCT01166126
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV treatment 2 terminated NCT05482074
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 treatment 2 withdrawn NCT02158520
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery treatment 2 completed NCT03033576
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma treatment 2 active_not_recruiting NCT00085189
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma treatment 2 completed NCT02858869
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases treatment 1 completed NCT05545969
Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma treatment 2 withdrawn NCT05009446
Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM No drug interventions treatment 0 recruiting NCT04180995
Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma treatment 2 unknown_status NCT04353050
Atypical MOLes and Melanoma Early Detection Study (MoleMed) No drug interventions diagnostic Not Available unknown_status NCT03178123
The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery treatment 2 active_not_recruiting NCT02978443
A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab treatment 2 terminated NCT05436990
Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor treatment 2 not_yet_recruiting NCT02126579
Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists No drug interventions treatment 1 / 2 completed